The FDA just approved a version of Narcan, the most commonly used version of the overdose prevention medicine naloxone, for over-the-counter sales. The move comes in response to overdose deaths steadily rising since the late ‘70s and around 100,000 Americans dying from overdose just last year. What took so long?

Guest: Nancy D. Campbell, department head at Rensselaer’s department of science and technology studies, author of OD: Naloxone and the Politics of Overdose.

If you enjoy this show, please consider signing up for Slate Plus. Slate Plus members get benefits like zero ads on any Slate podcast, bonus episodes of shows like Slow Burn and Amicus—and you’ll be supporting the work we do here on What Next. Sign up now at slate.com/whatnextplus to help support our work.

Make an impact this Earth Month by helping Macy’s on their mission to bring more parks to more people across the country. Go to macys.com/purpose to learn more.

Learn more about your ad choices. Visit megaphone.fm/adchoices